OGN - Organon & Co.
(NaN%)
Sell
Weak Growth
37%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 1.44%
Operating Income Growth is -22.17%
Net Income Growth is 11.56%
Earnings Per Share (EPS) Growth is 11.14%
Net Margin is 16.33%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.54
Debt Ratio is 1.01
Current Debt to Net Income Ratio is 0.01
Total Debt to Total Assets Ratio is 0.73
Cash Flow is MODERATE
Cash from Operations Growth is -6.88%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Organon & Co. (OGN)
organon is a dutch pharmaceutical company started in oss the netherlands. it is famous for "the pil" a birthcontrol pil. organon grew as a company and was taken over by schering plough and later on by merck and continues as msd in the netherlands. in the old days the compant was great, it used to be "gezellig" !Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Kevin Ali
Employees - 7,231
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.